OBJECTIVES: To prospectively use a non-invasive algorithm to identify asymptomatic, advanced non-alcoholic fatty liver disease (NAFLD) in a secondary care diabetes clinic and to determine the short-term effect of a multi-disciplinary team (MDT) approach in a liver clinic. RESEARCH DESIGN AND METHODS: NAFLD Fibrosis Score (NFS) was calculated in 64 asymptomatic patients with type 2 diabetes. Advanced fibrosis was identified using transient elastography and confirmed with liver biopsy. In a subsequent retrospective study, 95 patients newly referred to the NAFLD MDT clinic were investigated and the impact of the MDT approach assessed. RESULTS: 25/64 (39.0%) of patients with diabetes had a low NFS (<-1.455). 39/64 (61.0%) patients had a high or indeterminate NFS and were referred for review in the NAFLD MDT clinic, of which 23/39 attended for assessment. 19/23 (82.6%) were diagnosed with NAFLD, of which 6/19 (31.6%) patients had a positive transient elastography (≥8 kPa). Liver biopsy confirmed advanced fibrosis in 5/6 cases, with moderate fibrosis in 1 case. In the retrospective study, 65/95 (68.4%) new referrals to the NAFLD MDT clinic had a diagnosis of NAFLD. Over a median 98 days (IQR 70-182) follow-up, there was a significant improvement in weight (-0.8 kg; P = 0.024), total cholesterol (-0.2 mmol/L; P = 0.044), ALT (alanine transmaminase, -12.5 IU/L; P < 0.001) and GGT (gammu-glutamyl transferase, -13.0 IU/L; P < 0.0001). 7/28 (25%) of patients with diabetes achieved >5% weight loss. CONCLUSIONS: A significant proportion of asymptomatic patients attending type 2 diabetes clinics have undiagnosed advanced NAFLD fibrosis. An MDT approach to NAFLD results in short-term improvements in metabolic and liver parameters.
OBJECTIVES: To prospectively use a non-invasive algorithm to identify asymptomatic, advanced non-alcoholic fatty liver disease (NAFLD) in a secondary care diabetes clinic and to determine the short-term effect of a multi-disciplinary team (MDT) approach in a liver clinic. RESEARCH DESIGN AND METHODS: NAFLD Fibrosis Score (NFS) was calculated in 64 asymptomatic patients with type 2 diabetes. Advanced fibrosis was identified using transient elastography and confirmed with liver biopsy. In a subsequent retrospective study, 95 patients newly referred to the NAFLD MDT clinic were investigated and the impact of the MDT approach assessed. RESULTS: 25/64 (39.0%) of patients with diabetes had a low NFS (<-1.455). 39/64 (61.0%) patients had a high or indeterminate NFS and were referred for review in the NAFLD MDT clinic, of which 23/39 attended for assessment. 19/23 (82.6%) were diagnosed with NAFLD, of which 6/19 (31.6%) patients had a positive transient elastography (≥8 kPa). Liver biopsy confirmed advanced fibrosis in 5/6 cases, with moderate fibrosis in 1 case. In the retrospective study, 65/95 (68.4%) new referrals to the NAFLD MDT clinic had a diagnosis of NAFLD. Over a median 98 days (IQR 70-182) follow-up, there was a significant improvement in weight (-0.8 kg; P = 0.024), total cholesterol (-0.2 mmol/L; P = 0.044), ALT (alanine transmaminase, -12.5 IU/L; P < 0.001) and GGT (gammu-glutamyl transferase, -13.0 IU/L; P < 0.0001). 7/28 (25%) of patients with diabetes achieved >5% weight loss. CONCLUSIONS: A significant proportion of asymptomatic patients attending type 2 diabetes clinics have undiagnosed advanced NAFLD fibrosis. An MDT approach to NAFLD results in short-term improvements in metabolic and liver parameters.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Gastroenterology Date: 2012-05-15 Impact factor: 22.682
Authors: Abd A Tahrani; Asad Ali; Neil T Raymond; Safia Begum; Kiran Dubb; Shanaz Mughal; Biju Jose; Milan K Piya; Anthony H Barnett; Martin J Stevens Journal: Am J Respir Crit Care Med Date: 2012-06-21 Impact factor: 21.405
Authors: Stephen P Casey; William W Kemp; Catriona A McLean; Duncan J Topliss; Leon A Adams; Stuart K Roberts Journal: Scand J Gastroenterol Date: 2012-04-23 Impact factor: 2.423
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day Journal: Hepatology Date: 2007-04 Impact factor: 17.425
Authors: Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi Journal: Nat Rev Gastroenterol Hepatol Date: 2021-06-25 Impact factor: 46.802
Authors: David A Sheridan; Guru Aithal; William Alazawi; Michael Allison; Quentin Anstee; Jeremy Cobbold; Shahid Khan; Andrew Fowell; Stuart McPherson; Philip N Newsome; Jude Oben; Jeremy Tomlinson; Emmanouil Tsochatzis Journal: Frontline Gastroenterol Date: 2017-04-28
Authors: Jeffrey V Lazarus; Henry E Mark; Quentin M Anstee; Juan Pablo Arab; Rachel L Batterham; Laurent Castera; Helena Cortez-Pinto; Javier Crespo; Kenneth Cusi; M Ashworth Dirac; Sven Francque; Jacob George; Hannes Hagström; Terry T-K Huang; Mona H Ismail; Achim Kautz; Shiv Kumar Sarin; Rohit Loomba; Veronica Miller; Philip N Newsome; Michael Ninburg; Ponsiano Ocama; Vlad Ratziu; Mary Rinella; Diana Romero; Manuel Romero-Gómez; Jörn M Schattenberg; Emmanuel A Tsochatzis; Luca Valenti; Vincent Wai-Sun Wong; Yusuf Yilmaz; Zobair M Younossi; Shira Zelber-Sagi Journal: Nat Rev Gastroenterol Hepatol Date: 2021-10-27 Impact factor: 46.802
Authors: Jonathan M Hazlehurst; Conor Woods; Thomas Marjot; Jeremy F Cobbold; Jeremy W Tomlinson Journal: Metabolism Date: 2016-01-11 Impact factor: 8.694
Authors: Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman Journal: Gut Date: 2017-11-09 Impact factor: 23.059